Impact of Clinical Pharmacy Services on Medication Adherence and Clinical Outcomes in Post-Percutaneous Coronary Intervention Patients with ST-Elevation Myocardial Infarction
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 100
- 试验地点
- 1
研究概览
简要总结
This prospective interventional study aims to evaluate the impact of clinical pharmacy services on medication adherence and clinical outcomes in patients with ST-elevation myocardial infarction (STEMI) who have undergone primary percutaneous coronary intervention (PCI). Conducted at Vivekanandha Medical Care Hospital, the study will enroll 100 eligible STEMI patients randomized to intervention and control groups. The intervention group will receive structured clinical pharmacist-led services, including medication counseling, adherence monitoring using validated scales, patient education via telephonic communication, and management of drug-related problems. Primary outcomes include medication adherence improvement measured by the Morisky Medication Adherence Scale and reduction of major adverse cardiovascular events, with follow-ups at 3, 6, 9, and 12 months. Secondary outcomes assess quality of life and determinants of in-stent restenosis. The study addresses a critical gap in Indian cardiac care by integrating pharmacist interventions to improve patient outcomes and reduce complications post-PCI. Ethical approval has been obtained, and the study duration is December 2025 to July 2027.
研究设计
- 研究类型
- Interventional
- 分配方式
- Coin toss, Lottery, toss of dice, shuffling cards etc
- 盲法
- None
入排标准
- 年龄范围
- 18.00 Year(s) 至 65.00 Year(s)（—）
- 性别
- All
入选标准
- •Patients aged 18 years to 65 Years.
- •Patients diagnosed with ST-Elevation Myocardial Infarction (STEMI) and admitted to the hospital for its management.
- •Patients undergoing their first-ever Percutaneous Coronary Intervention (PCI) procedure as part of their STEMI treatment.
- •Patients willing to participate in the study and provide informed consent.
- •Patients or their caregivers who have access to a smartphone.
排除标准
- •Patients with chronic conditions such as carcinoma or other severe chronic illnesses that may impact study participation.
- •Patients who do not have access to a smartphone.
- •Patients unwilling to participate in the study.
- •Patients with cognitive impairment or any condition that prevents effective communication and participation.
- •Patients with a history of prior PCI or coronary artery bypass grafting (CABG).
- •If any patient developed restenosis soon after the PCI the sample will be sent to lab for testing P2Y12 to confirm the resistance towards the anti-platelet drugs, if any resistance patients will be removed from the study.
- •Patient those who are not willing for biomarker assessment during follow-up.
- •Patients who fail to attend any scheduled follow-up assessments, leading to incomplete data collection during the study period will be excluded.
研究者
Sajan Francis P
Yenepoya Pharmacy College and Research Center